Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lavage

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    167 result(s) found for: Lavage. Displaying page 5 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2016-001255-49 Sponsor Protocol Number: CACZ885X2205 Start Date*: 2016-08-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sar...
    Medical condition: Pulmonary sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037430 Pulmonary sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003473-17 Sponsor Protocol Number: CC-90001-IPF-001 Start Date*: 2017-09-14
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiop...
    Medical condition: IDIOPATHIC PULMONARY FIBROSIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10067761 Exacerbation of idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003301-26 Sponsor Protocol Number: IAFIPF001 Start Date*: 2013-09-20
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: A randomised placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020747-13 Sponsor Protocol Number: D0540C00014 Start Date*: 2010-07-16
    Sponsor Name:AstraZeneca AB
    Full Title: A double-blind, placebo controlled, randomised, parallel group phase IIa study to investigate the efficacy, tolerability, and safety of different dosing regimens of AZD8848 administered intranasall...
    Medical condition: Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001550-22 Sponsor Protocol Number: AMY-101_SAVE Start Date*: 2020-11-04
    Sponsor Name:Amyndas Pharmaceuticals S.A.
    Full Title: A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in patients with Acute Respiratory Distress Syndrome (ARDS) due to Covid-19.
    Medical condition: Acute Respiratory Distress Syndrome (ARDS) due to SARS-CoV-2 infection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004026-16 Sponsor Protocol Number: P060209 Start Date*: 2008-08-11
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: BIVIR : Essai randomisé en double insu comparant l'association oseltamivir et zanamivir à l'oseltamivir et placebo et au zanamivir et placebo dans le traitement curatif de la grippe, virologiquemen...
    Medical condition: Patients en période de grippe clinique déclarée au niveau national et régional, présentant les sympyômes généraux et ayant un test diagnostic positif pour la grippe de type A.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022000 Grippe de type A PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004167-56 Sponsor Protocol Number: 027SC06104 Start Date*: 2007-02-15
    Sponsor Name:ANGELINI
    Full Title: Prulifloxacin versus levofloxacin in the treatment of patients with Acute Exacerbations of Chronic Bronchitis AECB
    Medical condition: Outpatient with acute exacerbations of chronic bronchitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061736 Bronchitis bacterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) PT (Completed) ES (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003343-29 Sponsor Protocol Number: RG_12-179 Start Date*: 2013-01-18
    Sponsor Name:University of Birmingham
    Full Title: Simvastatin as adjuvant therapy to correct neutrophil dysfunction in older pneumonia patients - a randomised double blind placebo controlled trial
    Medical condition: Acute episodes of Pneumonia and sepsis in older adults
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10035664 Pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005301-22 Sponsor Protocol Number: IPR110723 Start Date*: 2008-02-07
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhini...
    Medical condition: Seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005340-12 Sponsor Protocol Number: IPR101987 Start Date*: 2006-03-23
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 14 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in an environmental exposition unit (Vienna Challenge Chamber) in ...
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039776 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006000-11 Sponsor Protocol Number: IPR107498 Start Date*: 2007-01-01
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An 8 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in the Vienna Challenge Chamber in subjects with seasonal allergic...
    Medical condition: Seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001204-21 Sponsor Protocol Number: CTBM100CDE02 Start Date*: 2014-11-17
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An 8 week open-label interventional multicenter study to evaluate the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥ 6 years of age, chronically infected with Ps...
    Medical condition: Chronic lung infection with Pseudomonas aeruginosa in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    18.0 100000004862 10021860 Infection Pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003036-23 Sponsor Protocol Number: 19SM5101 Start Date*: 2019-12-02
    Sponsor Name:Imperial College London
    Full Title: Mechanisms of adverse effects of long-acting beta-agonists in asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003638 Atopic asthma LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003565 Asthmatic LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10015575 Exacerbation of asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-002035-28 Sponsor Protocol Number: TBM100C2301 (TIP002) Start Date*: 2005-09-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects
    Medical condition: pulmonary P aeruginosa infection in patient with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020141-26 Sponsor Protocol Number: D3320C00001 Start Date*: 2010-08-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an oral tablet in Subjects with Mild COPD Following Seg...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003881-96 Sponsor Protocol Number: EPAFC Start Date*: 2016-05-17
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER
    Full Title: Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing classic treatment protocols with classic treatment together with antibiotic treatment o...
    Medical condition: cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004244-33 Sponsor Protocol Number: ATYR1923-C-002 Start Date*: 2019-10-21
    Sponsor Name:aTyr Pharma, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis
    Medical condition: Pulmonary Sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037430 Pulmonary sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002836-97 Sponsor Protocol Number: 240193 Start Date*: 2012-12-20
    Sponsor Name:Tartu University Hospital
    Full Title: Pharmacokinetics of penicillin, ampicillin and gentamicin in near- term and full-term neonates
    Medical condition: neonatal sepsis, pneumonia and meningitis
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002806-30 Sponsor Protocol Number: PUL-042-402 Start Date*: 2018-12-14
    Sponsor Name:Pulmotect, Inc.
    Full Title: A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Study of PUL-042 Inhalation Solution in Rhinovirus-induced Symptoms in Current Smokers with Gold Stage 0 Chronic Obstructive Pulmonary Di...
    Medical condition: GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 0 Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-004318-16 Sponsor Protocol Number: DAS181-3-01 Start Date*: 2020-01-16
    Sponsor Name:Ansun Biopharma, Inc.
    Full Title: A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
    Medical condition: Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10033796 Parainfluenzae viral infections HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 03:23:08 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA